Goldman Sachs
CINC

Goldman Sachs’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

Goldman Sachs’s Portfolio CINC Stock Details CINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-79,450
Closed -$976K – 6438
2022
Q4 		$976K Buy
79,450
+10,627
+15% +$253K ﹤0.01% 4440
2022
Q3 		$2.26M Buy
68,823
+58,082
+541% +$1.64M ﹤0.01% 3873
2022
Q2 		$202K Sell
10,741
-2,821
-21% -$54K ﹤0.01% 5634
2022
Q1 		$238K Buy
+13,562
New +$278K ﹤0.01% 5787

Goldman Sachs's CINC Position: Q1 2023 in Review

Goldman Sachs sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q1 2023, closing a stake of 79,450 shares — an estimated $976K sold.

Goldman Sachs first reported a position in CINC in Q1 2022 and held it in 4 quarters. The position peaked at $2.26M in Q3 2022. 0 funds tracked by Wall St. Rank hold CINC as of Q1 2023.

  • Goldman Sachs reported no remaining CinCor Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 79,450 CinCor Pharma, Inc. Common Stock shares in Q1 2023, an estimated $976K.
  • Goldman Sachs first reported a position in CinCor Pharma, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Goldman Sachs's CinCor Pharma, Inc. Common Stock position peaked at $2.26M in Q3 2022.
  • 0 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.